Author: Tan, Zhaoli; Gao, Lihua; Wang, Yan; Yin, Huihui; Xi, Yongyi; Wu, Xiaojie; Shao, Yong; Qiu, Weiyi; Du, Peng; Shen, Wenlong; Fu, Ling; Jia, Ru; Zhao, Chuanhua; Zhang, Yun; Zhao, Zhihu; Sun, Zhiwei; Chen, Hongxing; Hu, Xianwen; Xu, Jianming; Wang, Youliang
Title: PRSS contributes to cetuximab resistance in colorectal cancer Document date: 2020_1_1
ID: tymoeyoo_2
Snippet: Anti-EGFR therapies based on blocking ligand binding with monoclonal antibodies (mAbs) are widely used in clinical practice for EGFR-expressing cancers (3, 6) , and the development of anti-EGFR mAbs was a milestone in mCRC treatment. The U.S. Food and Drug Administration approved cetuximab, a chimeric mAb, for the treatment of patients with irinotecan-refractory and/or oxaliplatinrefractory mCRC (7) (8) (9) (10) . However, cetuximab therapy has h.....
Document: Anti-EGFR therapies based on blocking ligand binding with monoclonal antibodies (mAbs) are widely used in clinical practice for EGFR-expressing cancers (3, 6) , and the development of anti-EGFR mAbs was a milestone in mCRC treatment. The U.S. Food and Drug Administration approved cetuximab, a chimeric mAb, for the treatment of patients with irinotecan-refractory and/or oxaliplatinrefractory mCRC (7) (8) (9) (10) . However, cetuximab therapy has had only a modest impact on mCRC, achieving only approximately 10% objective response rates when used as a monotherapy for chemorefractory mCRC. The key reasons for the limited success of cetuximab in mCRC include severe primary (de novo) and secondary (acquired) resistance to EGFR-targeted therapies (11) .
Search related documents:
Co phrase search for related documents- Anti EGFR therapy and mcrc treatment: 1, 2
- cetuximab therapy and monoclonal antibody: 1
Co phrase search for related documents, hyperlinks ordered by date